Bleeding on brain [cerebral haemorrhage], chest pain [chest pain], severe fall in my apartment [fall], two cracked ribs [rib fracture], extreme pain [pain], swelling [swelling], shoulder pain [musculoskeletal pain], right knee extreme pain [arthralgia], very tired, slept three hours after third injection [fatigue].This serious, regulatory authority, spontaneous report was received from a consumer in united states.This report concerns a patient of unknown age and gender who experienced bleeding on brain, chest pain, severe fall in my apartment, two cracked ribs, extreme pain, swelling, shoulder pain, right knee extreme pain, and very tired, slept three hours after third injection during treatment with intra-articular euflexxa (sodium hyaluronate) solution for injection unknown concentration of unknown dose, 3 week period, for an unknown indication from 2017 to 2017.The patient reported bleeding on brain, right knee extreme pain, chest, shoulders.They reported they experienced a severe fall in their apartment at 5:20 am on an unspecified date in 2017.Two cracked ribs.They were hospitalized (date unspecified) and sent to rehab for three weeks.They reported extreme pain, swelling, and being very tired.They slept for three hours after the third injection of euflexxa.Action taken with euflexxa was dose not changed.At the time of this report, the outcome of the events was unknown.Medical history was not reported.The following concomitant medication was reported: metoprolol, resveratrol, b12, vitamin c, vitamin d3.At the time of reporting the case outcome was unknown.Overall listedness (core label) is unlisted.Reporter causality: related.Company causality: related.Other case numbers: case number, others = mw5070072.This ae occurred in the us and concerns the medical device euflexxa.Please report to your local health authority if required by local law.This ae is not reportable in eu because it did not occur in a eu + efta country and did not result in a corrective action by the manufacturer no corrective action was done by the manufacturer or requested by regulators.(b)(4).
|